(Q38252429)

1 September 2017

1 reference

title

Progress and controversies: Radiation therapy for prostate cancer (English)

1 reference

Adaptive radiation therapy

1 September 2017

main subject

0 references

1 reference

Neil E Martin

1

1 reference

1 September 2017

Anthony V D'Amico

series ordinal

2

1 reference

1 September 2017

language of work or name

English

0 references

publication date

18 September 2014

1 reference

1 September 2017

1 reference

1 September 2017

volume

64

1 reference

1 September 2017

issue

6

1 reference

1 September 2017

page(s)

389-407

1 reference

Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study.

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Cost implications of the rapid adoption of newer technologies for treating prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

The sources of the SGR "hole".

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Urologists' use of intensity-modulated radiation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Increased survival with enzalutamide in prostate cancer after chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Abiraterone and increased survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Time trends and local variation in primary treatment of localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Patient-reported quality of life during radiation treatment for localized prostate cancer: results from a prospective phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Individualizing quality-of-life outcomes reporting: how localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Prediction of erectile function following treatment for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Risk of second primary tumors in men diagnosed with prostate cancer: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Identification of intermediate-risk prostate cancer patients treated with radiotherapy suitable for neoadjuvant hormone studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Mortality results from a randomized prostate-cancer screening trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Contemporary risk profile of prostate cancer in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

21 January 2018

Overdiagnosis in cancer

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Preoperative 3-Tesla multiparametric endorectal magnetic resonance imaging findings and the odds of upgrading and upstaging at radical prostatectomy in men with clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

ESUR prostate MR guidelines 2012

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Histology core-specific evaluation of the European Society of Urogenital Radiology (ESUR) standardised scoring system of multiparametric magnetic resonance imaging (mpMRI) of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Clinical outcome of patients treated with 3D conformal radiation therapy (3D-CRT) for prostate cancer on RTOG 9406.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Life, liberty, and the pursuit of protons: an evidence-based review of the role of particle therapy in the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Conformal radiation treatment of prostate cancer using inversely-planned intensity-modulated photon beams produced with dynamic multileaf collimation

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Preliminary toxicity analysis of 3-dimensional conformal radiation therapy versus intensity modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group 0126 prostate cancer trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Radiation dose-volume effects in radiation-induced rectal injury

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Radiation dose-volume effects of the urinary bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Outcomes after intensity-modulated versus conformal radiotherapy in older men with nonmetastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Tadalafil for prevention of erectile dysfunction after radiotherapy for prostate cancer: the Radiation Therapy Oncology Group [0831] randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Predictors of response to sildenafil citrate following radiation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Increasing use of dose-escalated external beam radiation therapy for men with nonmetastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Proton therapy expansion under current United States reimbursement models

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Five-year outcomes from 3 prospective trials of image-guided proton therapy for prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Proton therapy for prostate cancer: the initial Loma Linda University experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Late gastrointestinal toxicities following radiation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

The linear-quadratic formula and progress in fractionated radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Hypofractionation for clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Long-term results of hypofractionated radiation therapy for breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Stereotactic body radiotherapy for organ-confined prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Stereotactic body radiotherapy for localized prostate cancer: pooled analysis from a multi-institutional consortium of prospective phase II trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: comparison of toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Patient and treatment factors associated with complications after prostate brachytherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Radiotherapy and short-term androgen deprivation for localized prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Phase II trial of combined high-dose-rate brachytherapy and external beam radiotherapy for adenocarcinoma of the prostate: preliminary results of RTOG 0321

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

STUDIES ON PROSTATIC CANCER

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Androgen deprivation therapy: evidence-based management of side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Duration of androgen suppression in the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Phase III Trial Comparing Whole-Pelvic Versus Prostate-Only Radiotherapy and Neoadjuvant Versus Adjuvant Combined Androgen Suppression: Radiation Therapy Oncology Group 9413

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

The timing of salvage radiotherapy after radical prostatectomy: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/American Urological Association guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Adjuvant versus salvage radiation therapy for prostate cancer and the risk of death

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Radical prostatectomy or watchful waiting in early prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Radical prostatectomy versus observation for localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

The role of anxiety in prostate carcinoma: a structured review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Why do men choose one treatment over another?: a review of patient decision making for localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Symptom indexes to assess outcomes of treatment for early prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Integrating patient reported outcomes with clinical cancer registry data: a feasibility study of the electronic Patient-Reported Outcomes From Cancer Survivors (ePOCS) system

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

Duration of Short-Course Androgen Suppression Therapy and the Risk of Death As a Result of Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3322%2FCAAC.21250

21 January 2018

Identifiers

DOI

10.3322/CAAC.21250

1 reference

1 September 2017

1 reference